Renal targeting of captopril using captopril-lysozyme conjugate enhances its antiproteinuric effect in adriamycin-induced nephrosis

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 5, Issue 4, 2004, Pages 197-202

  Windt, Willemijn A K M ^a,c   Prakash, Jai ^b   Kok, Robbert Jan ^b   Moolenaar, Frits ^b   Kluppel, C Alex ^a   de Zeeuw, Dick ^a   van Dokkum, Richard P E ^a   Henning, Robert H ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

^c Department of Clinical Pharmacology ^*  (Netherlands)

Author keywords

ACE inhibition; Low molecular weight protein; Lysozyme; Proteinuria; Renal targeting

Indexed keywords

CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE; DOXORUBICIN; LYSOZYME;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE MONITORING; CONJUGATE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG COMPETITION; DRUG EFFICACY; DRUG MEGADOSE; DRUG TARGETING; DRUG TISSUE LEVEL; ENZYME ACTIVITY; ENZYME INHIBITION; HIGH SODIUM INTAKE; KIDNEY PROXIMAL TUBULE; MALE; NEPHROSIS; NONHUMAN; PROTEINURIA; RAT; RENAL PROTECTION;

EID: 14844353575     PISSN: 14703203     EISSN: None     Source Type: Journal    
DOI: 10.3317/jraas.2004.040     Document Type: Article

References (20)

1. Navis G, Faber HJ, de Zeeuw D, de Jong PE.ACE inhibitors and the kidney. A risk-benefit assessment. Drug Saf 1996; 15: 200-11.
2. Pisoni R, Faraone R, Ruggenent P, Remuzzi G. Inhibitors of the renin-angiotensin system reduce the rate of GFR decline and end-stage renal disease in patients with severe renal insufficiency. J Nephrol 2002; 15:428-30.
3. Palla R, Panichi V, Finato V et al. Effect of increasing doses of lisinopril on proteinuria of normotensive patients with IgA nephropathy and normal renal function. Int J Clin Pharmacol Res 1994;14:35-43.
4. Textor SC, Bravo EL, Fouad FM, Tarazi RC. Hyperkalemia in azotemic patients during angiotensin-converting enzyme inhibition and aldosterone reduction with captopril. Am J Med 1982;73 719-25.
5. Heeg JE, de Jong PE, van der Hem GK, de Zeeuw D. Efficacy and variability of the antiproteinuric effect of ACE inhibition by lisinopril. Kidney Int 1989;36:272-9.
6. Buter H, Hemmelder MH, Navis G, de Jong PE, de Zeeuw D. The blunting of the antiproteinuric efficacy of ACE inhibition by high sodium intake can be restored by hydrochlorothiazide. Nephrol Dial Transplant 1998; 13:1682-5.
7. Kocks MJ, Buikema H, Gschwend S, Boomsma F, de Zeeuw D, Navis G. High dietary sodium blunts effects of angiotensin-converting enzyme inhibition on vascular angiotensin I-toangiotensin II conversion in rats. J Cardiovasc Pharmacol 2003;42:601-06.
8. Laverman GD, Van Goor H, Henning RH, de Jong PE, de Zeeuw D, Navis G. Renoprotective effects of VPI versus ACEI in normotensive nephrotic rats on different sodium intakes. Kidney Int 2003; 63 64-71.
9. Kok RJ, Grijpstra F, Walthuis RB, Moolenaar F, de Zeeuw D, Meijer DK. Specific delivery of captopril to the kidney with the prodrug captopril-lysozyme. J Pharmacol Exp Ther 1999;288: 281-5.
10. Kok RJ, Haverdings RF, Grijpstra F et al. Targeting of captopril to the kidney reduces renal angiotensin-converting enzyme activity without affecting systemic blood pressure.J Pharmacol Exp Ther 2002;301:1139-43.
11. Kok RJ, Visser J, Moolenaar F, de Zeeuw D, Meijer DK. Bioanalysis of captopril: two sensitive high-performance liquid chromatographic methods with pre- or postcolumn fluorescent labeling.J Chromatogr B Biomed Sci Appl 1997;693:181-9.
12. Koiter J, Navis G, de Jong PE,Van Gilst WH, de Zeeuw D. Sample dilution: a methodological pitfall in the measurement of tissue but not serum ACE-activity. J Pharmacol Toxicol Methods 1998; 39 45-9.
13. Prakash J, van Loenen-Weemaes AM, Haas M et al. Renal-selective delivery and ACE inhibition by subcutaneously administered captopril-lysozyme. Drug Metab Dispos 2005 (Epub ahead of print).
14. Ondetti MA, Cushman DW. Inhibition of the renin-angiotensin system. A new approach to the therapy of hypertension. J Med Chem 1981;24:355-61.
15. Franssen EJ, van Amsterdam RG, Visser J, Moolenaar F, de Zeeuw D, Meijer DK. Low molecular weight proteins as carriers for renal drug targeting: naproxen-lysozyme. Pharm Res 1991; 8:1223-30.
16. Largo R, Gomez-Garre D, Soto K et al. Angiotensin-converting enzyme is upregulated in the proximal tubules of rats with intense proteinuria. Hypertension 1999; 33:732-9.
17. Mezzano SA, Aros CA, Droguett A et al. Renal angiotensin II up-regulation and myofibroblast activation in human membranous nephropathy. Kidney Int Suppl 2003;(86):S39-S45.
18. Wapstra FH, Navis GJ, Van Goor H et al. ACE inhibition preserves heparan sulfate proteoglycans in the glomerular basement membrane of rats with established adriamycin nephropathy. Exp Nephrol 2001; 9:21-7.
19. Bos H, Laverman GD, Henning RH et al. Involvement of renal ACE activity in proteinuria-associated renal damage in untreated and treated adriamycin nephrotic rats.JRAAS 2003; 4:106-12.
20. Laverman GD, Navis G, Henning RH, de Jong PE, de Zeeuw D. Dual renin-angiotensin system blockade at optimal doses for proteinuria. Kidney Int 2002;62:1020-5.